artesunate and mefloquine — Competitive Intelligence Brief

artesunate and mefloquine (artesunate and mefloquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium falciparum heme iron (artesunate); parasite digestive vacuole and mitochondria (mefloquine) Infectious Disease Small molecule

Target snapshot

artesunate and mefloquine (artesunate and mefloquine) — Mepha Ltd.. Artesunate and mefloquine work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and organelles, while mefloquine disrupts parasite digestive vacuole function and mitochondrial activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
artesunate and mefloquine TARGET	artesunate and mefloquine	Mepha Ltd.	marketed	Antimalarial combination	Plasmodium falciparum heme iron (artesunate); parasite digestive vacuole and mitochondria (mefloquine)
SP-IPTp	SP-IPTp	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
Quinine plus sulfadoxine-pyrimethamine	Quinine plus sulfadoxine-pyrimethamine	Albert Schweitzer Hospital	marketed	Antimalarial combination	Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase
Artemether, Lumefantrine Drug Combination	Artemether, Lumefantrine Drug Combination	University of Yaounde 1	marketed	Antimalarial combination	Plasmodium falciparum heme and mitochondrial function
IPTp-SP	IPTp-SP	Kenya Medical Research Institute	marketed	Antifolate antimalarial combination	Dihydrofolate reductase (DHFR)
Sulfadoxine-pyrimethamine plus artesunate	Sulfadoxine-pyrimethamine plus artesunate	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Dihydrofolate reductase, dihydropteroate synthase (sulfadoxine-pyrimethamine); mitochondrial electron transport (artesunate)
artesunate-lapdap	artesunate-lapdap	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Plasmodium falciparum dihydrofolate reductase (lapdap component); artemisinin mechanism not fully elucidated but involves heme interaction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class